Zoetis Inc (ZTS)
175.18
-6.77
(-3.72%)
USD |
NYSE |
Nov 04, 16:00
175.25
+0.07
(+0.04%)
After-Hours: 20:00
Zoetis Revenue (Quarterly): 2.361B for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 2.361B |
| March 31, 2024 | 2.19B |
| December 31, 2023 | 2.213B |
| September 30, 2023 | 2.151B |
| June 30, 2023 | 2.18B |
| March 31, 2023 | 2.00B |
| December 31, 2022 | 2.04B |
| September 30, 2022 | 2.002B |
| June 30, 2022 | 2.052B |
| March 31, 2022 | 1.986B |
| December 31, 2021 | 1.967B |
| September 30, 2021 | 1.99B |
| June 30, 2021 | 1.948B |
| March 31, 2021 | 1.871B |
| December 31, 2020 | 1.807B |
| September 30, 2020 | 1.786B |
| June 30, 2020 | 1.548B |
| March 31, 2020 | 1.534B |
| December 31, 2019 | 1.674B |
| September 30, 2019 | 1.584B |
| June 30, 2019 | 1.547B |
| March 31, 2019 | 1.455B |
| December 31, 2018 | 1.564B |
| September 30, 2018 | 1.48B |
| June 30, 2018 | 1.415B |
| Date | Value |
|---|---|
| March 31, 2018 | 1.366B |
| December 31, 2017 | 1.46B |
| September 30, 2017 | 1.347B |
| June 30, 2017 | 1.269B |
| March 31, 2017 | 1.231B |
| December 31, 2016 | 1.277B |
| September 30, 2016 | 1.241B |
| June 30, 2016 | 1.208B |
| March 31, 2016 | 1.162B |
| December 31, 2015 | 1.274B |
| September 30, 2015 | 1.214B |
| June 30, 2015 | 1.175B |
| March 31, 2015 | 1.102B |
| December 31, 2014 | 1.32B |
| September 30, 2014 | 1.21B |
| June 30, 2014 | 1.158B |
| March 31, 2014 | 1.097B |
| December 31, 2013 | 1.254B |
| September 30, 2013 | 1.103B |
| June 30, 2013 | 1.114B |
| March 31, 2013 | 1.09B |
| December 31, 2012 | 1.176B |
| September 30, 2012 | 1.019B |
| June 30, 2012 | 1.094B |
| March 31, 2012 | 1.047B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.534B
Minimum
Mar 2020
2.361B
Maximum
Jun 2024
1.963B
Average
1.99B
Median
Sep 2021
Revenue (Quarterly) Benchmarks
| Pfizer Inc | 17.70B |
| Alnylam Pharmaceuticals Inc | 500.92M |
| Biomarin Pharmaceutical Inc | 745.74M |
| Corcept Therapeutics Inc | 182.55M |
| Ionis Pharmaceuticals Inc | 225.25M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 624.00M |
| Total Expenses (Quarterly) | 1.455B |
| EPS Diluted (Quarterly) | 1.37 |
| Enterprise Value | 87.42B |
| Gross Profit Margin (Quarterly) | 71.71% |
| Profit Margin (Quarterly) | 26.43% |
| Earnings Yield | 2.92% |
| Operating Earnings Yield | 4.00% |
| Normalized Earnings Yield | 3.109 |